Randomised phase 2 trial of nivolumab and radiotherapy versus nivolumab alone in advanced non-small cell lung cancer progressing after first line chemotherapy

The aim of this study is to determine the activity and safety of treating an asymptomatic, extrapulmonary metastasis with a single fraction of SABR, during immunotherapy with nivolumab in advanced NSCLC progressing after 1 or 2 lines of chemotherapy.

Primary Sponsor

The University of Sydney

Collaborating Groups

Australasian Lung Cancer Trials Group (ALTG) and Trans Tasman Radiation Oncology Group (TROG)

Closing Date of Accrual

30 June 2019

Trial Chairperson

A/Prof Paul Mitchell, Austin Health, VIC
TROG Chair: Dr Shankar Siva, Peter MacCallum Cancer Centre, VIC

Trial Contact

nivorad@ctc.usyd.edu.au

Related Post

David, Jasmine and Susan Goode, re Kokoda Challenge to support TROG Cancer Research
27 May, 2025

Intrepid trekkers to take on Kokoda Challenge for TROG

LATEST NEWS: 27 May 2025 A team of five

Clinical Trials Day 2025 stand at Calvary Mater Newcastle
27 May, 2025

Clinical Trials Day celebrations help spread the work about TROG’s work

LATEST NEWS: 27 MAY 2025 TROG members and staff